BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 30691317)

  • 1. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
    Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
    Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid/Hyaluronic Acid-Coated Doxorubicin-Fe
    Liang J; Yang X; Liu D; Cong M; Song Y; Bai S
    AAPS PharmSciTech; 2020 Aug; 21(6):235. PubMed ID: 32803528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
    Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
    Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
    Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
    Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced anti-tumor efficacy and reduced cardiotoxicity of doxorubicin delivered in a novel plant virus nanoparticle.
    Alemzadeh E; Dehshahri A; Dehghanian AR; Afsharifar A; Behjatnia AA; Izadpanah K; Ahmadi F
    Colloids Surf B Biointerfaces; 2019 Feb; 174():80-86. PubMed ID: 30445253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment.
    Pan C; Liu Y; Zhou M; Wang W; Shi M; Xing M; Liao W
    Int J Nanomedicine; 2018; 13():1119-1137. PubMed ID: 29520140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
    Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
    Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.
    Han HS; Thambi T; Choi KY; Son S; Ko H; Lee MC; Jo DG; Chae YS; Kang YM; Lee JY; Park JH
    Biomacromolecules; 2015 Feb; 16(2):447-56. PubMed ID: 25565417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
    Cui T; Zhang S; Sun H
    Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of doxorubicin by CSA-binding nanoparticles for choriocarcinoma treatment.
    Zhang B; Cheng G; Zheng M; Han J; Wang B; Li M; Chen J; Xiao T; Zhang J; Cai L; Li S; Fan X
    Drug Deliv; 2018 Nov; 25(1):461-471. PubMed ID: 29426237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
    Sun B; Deng C; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy.
    Gautam M; Thapa RK; Gupta B; Soe ZC; Ou W; Poudel K; Jin SG; Choi HG; Yong CS; Kim JO
    Expert Opin Drug Deliv; 2020 Mar; 17(3):423-434. PubMed ID: 32028805
    [No Abstract]   [Full Text] [Related]  

  • 16. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined photothermal-chemotherapy of breast cancer by near infrared light responsive hyaluronic acid-decorated nanostructured lipid carriers.
    Zheng S; Nguyen VD; Song SY; Han J; Park JO
    Nanotechnology; 2017 Oct; 28(43):435102. PubMed ID: 28783035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
    Zeng X; Morgenstern R; Nyström AM
    Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer.
    Li J; Cai P; Shalviri A; Henderson JT; He C; Foltz WD; Prasad P; Brodersen PM; Chen Y; DaCosta R; Rauth AM; Wu XY
    ACS Nano; 2014 Oct; 8(10):9925-40. PubMed ID: 25307677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial targeted doxorubicin derivatives delivered by ROS-responsive nanocarriers to breast tumor for overcoming of multidrug resistance.
    Zhong XC; Shi MH; Liu HN; Chen JJ; Wang TT; Lin MT; Zhang ZT; Zhou Y; Lu YY; Xu WH; Gao JQ; Xu DH; Han M; Chen YD
    Pharm Dev Technol; 2021 Jan; 26(1):21-29. PubMed ID: 33070673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.